Ixabepilone development across the breast cancer continuum: a paradigm shift

References

• O’ShaughnessyJMilesDVukeljaSSuperior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial resultsJ Clin Oncol2002202812282312065558
   PubMed Web of Science ®Google Scholar
• MelemedASO’ShaughnessyJNagSPhase III study of gemcitabine plus paclitaxel compared with paclitaxel alone in patients with unrespectable, locally recurrent, or metastatic breast cancer [abstract]Presented at the 2007 ASCO Breast Cancer Symposium2007 Sep 7–8San Francisco, CA, USA
   Google Scholar
• MartinMRuizAMuñozMSpanish Breast Cancer Research Group (GEICAM) trial. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase II Spanish Breast Cancer Research Group (GEICAM) trialLancet Oncol2007821922517329192
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med20063552733274317192538
   PubMed Web of Science ®Google Scholar
• von MinckwitzGZielinskiCMaarteenseECapecitabine versus capecitabine plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) [abstract]J Clin Oncol200826Suppl47S
   Google Scholar
• MillerKDWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med20073572666267618160686
   PubMed Web of Science ®Google Scholar
• MilesDChanARomieuGRandomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [abstract]J Clin Oncol200826Suppl1008S
   Google Scholar
• FerliniCRaspaglioGCicchillittiLLooking at resistance mechanisms for microtubule interacting drugs: does TUBB3 work?Curr Cancer Drug Targets2007770471218220531
   PubMed Web of Science ®Google Scholar
• ChienAJMoasserMMCellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquiredSemin Oncol200835Suppl 2S1S1418410794
   PubMed Web of Science ®Google Scholar
• Gonzalez-AnguloAMMorales-VasquezFHortobagyiGNOverview of resistance to systemic therapy in patients with breast cancerAdv Exp Med Biol200760812217993229
   PubMed Web of Science ®Google Scholar
• GoodinSKaneMPRubinEHEpothilones: mechanism of action and biological activityJ Clin Oncol2004222015202515143095
   PubMed Web of Science ®Google Scholar
• LeeJJSwainSMDevelopment of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)Semin Oncol200532Suppl 7S22S2616360719
   PubMed Web of Science ®Google Scholar
• PivotXDufresneAVillanuevaCEfficacy and safety of ixabepilone, a novel epothilone analogueClin Breast Cancer2007754354917509162
   PubMed Web of Science ®Google Scholar
• GoodinSNovel cytotoxic agents: epothilonesAm J Health Syst Pharm200865Suppl 3S10S1518463327
   PubMed Web of Science ®Google Scholar
• VahdatLIxabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanismsOncologist20081321422118378531
   PubMed Web of Science ®Google Scholar
• BodeCJGuptaMLJrReiffEASuprenantKAGeorgGIHimesRHEpothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubulesBiochemistry2002413870387411900528
   PubMed Web of Science ®Google Scholar
• CortesJBaselgaJTargeting the microtubules in breast cancer beyond taxanes: the epothilonesOncologist20071227128017405891
   PubMed Web of Science ®Google Scholar
• NettlesJHLiHCornettBKrahnJMSnyderJPDowningKHThe binding mode of epothilone A on alpha, beta-tubulin by electron crystallographyScience200430586686915297674
   PubMed Web of Science ®Google Scholar
• LeeFYFSmyklaRJohnstonKPreclinical efficacy spectrum and pharmacokinetics of ixabepiloneCancer Chemother Pharmacol20096320121218350296
   PubMed Web of Science ®Google Scholar
• ParadisoAMangiaAChiriattiABiomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancerAnn Oncol200516Suppl 4iv14iv1915923415
   PubMed Web of Science ®Google Scholar
• SèvePIsaacSTrédanOExpression of class III β-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based therapyClin Cancer Res2005115481548616061864
   PubMed Web of Science ®Google Scholar
• BaselgaJZambettiMLlombart-CussacAPhase II genomics study of ixabepilone as neoadjuvant treatment for breast cancerJ Clin Oncol20092752653419075286
   PubMed Web of Science ®Google Scholar
• DenduluriNLowJALeeJJPhase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanesJ Clin Oncol2007253421342717606971
   PubMed Web of Science ®Google Scholar
• LowJAWedamSBLeeJJPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancerJ Clin Oncol2005232726273415837987
   PubMed Web of Science ®Google Scholar
• PerezEALerzoGPivotXEfficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistance to an anthracycline, a taxane, and capecitabineJ Clin Oncol2007253407341417606974
   PubMed Web of Science ®Google Scholar
• RochéHYelleLCognettiFPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapyJ Clin Oncol2007253415342017606972
   PubMed Web of Science ®Google Scholar
• ThomasETaberneroJFornierMPhase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistance metastatic breast cancerJ Clin Oncol2007253399340617606975
   PubMed Web of Science ®Google Scholar
• ThomasESGomezHLLiRKIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol2007255210521717968020
   PubMed Web of Science ®Google Scholar
• HortobagyiGNPerezEVrdoljakEAnalysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized phase III trials [abstract]Presented at the 2008 ASCO Breast Cancer Symposium2008 Sep 5–7Washington, DC, USA
   Google Scholar
• HorakCELeeFYXuLHigh beta-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis [abstract]J Clin Oncol200927Suppl15S
   Google Scholar
• FisherBBrownAMamounasEEffect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18J Clin Oncol199715248324939215816
   PubMed Web of Science ®Google Scholar
• GradisharWJDocetaxel as neoadjuvant chemotherapy in patients with stage III breast cancerOncology (Williston Park)199711Suppl 815189364536
   PubMedGoogle Scholar
• BuzdarAUSingletarySETheriaultRLProspective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancerJ Clin Oncol1999173412341710550135
   PubMed Web of Science ®Google Scholar
• AmatSBougnouxPPenault-LlorcaFNeoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rateBr J Cancer2003881339134512778058
   PubMed Web of Science ®Google Scholar
• EstévezLGCuevasJMAntónAWeekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter studyClin Cancer Res2003968669212576436
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov [homepage on the Internet]Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer Available at: http://clinicaltrials.gov/ct2/show/NCT00455533. Accessed March 9, 2010.
   Google Scholar
• Clinicaltrials.gov [homepage on the Internet]Combination Chemotherapy Followed By Docetaxel or Ixabepilone in Treating Patients Who Have Undergone Surgery for Nonmetastatic Breast Cancer Available from: http://clinicaltrials.gov/ct2/show/NCT00630032. Accessed March 9, 2010.
   Google Scholar
• Clinicaltrials.gov [homepage on the Internet]A Randomized Trial of IXEMPRA versus TAXOL in Adjuvant Therapy of Triple Negative Breast Cancer (TITAN) Available from: http://clinicaltrials.gov/ct2/show/NCT00789581. Accessed March 9, 2010.
   Google Scholar
• MoulderSLiHWangMA phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2 positive metastatic breast cancer: an Eastern cooperative oncology group trialBreast Cancer Res Treat201011966367120012354
   PubMed Web of Science ®Google Scholar
• RugoHSCamponeMAmadoriDRandomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC) [abstract]J Clin Oncol200927Suppl15S
   Google Scholar
• JonesSEErbanJOvermoyerBRandomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancerJ Clin Oncol2005235542555116110015
   PubMed Web of Science ®Google Scholar
• NabholtzJMSennHJBezwodaWRProspective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study GroupJ Clin Oncol1999171413142410334526
   PubMed Web of Science ®Google Scholar
• BonneterreJRochéHMonnierADocetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline failureBr J Cancer2002871210121512439707
   PubMed Web of Science ®Google Scholar
• RobertNLeyland-JonesBAsmarLRandomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2–overexpressing metastatic breast cancerJ Clin Oncol2006242786279216782917
   PubMed Web of Science ®Google Scholar
• PerezEAPivotXVrdoljakEA prospective characterization of the resolution of ixabepilone-induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancerCancer Res2009696140
   Web of Science ®Google Scholar
• BunnellCVahdatLSchwartzbergLPhase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancerClin Breast Cancer2008823424118650153
   PubMed Web of Science ®Google Scholar
• ThomasESIxabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatmentJ Clin Oncol200826222318445853
   PubMed Web of Science ®Google Scholar
• JassemJThomasEGomezHPhase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: subgroup analysis of patients receiving ixabepilone in the first-line setting [abstract]Eur J Cancer20075Suppl213
   Web of Science ®Google Scholar
• VahdatLFeinLEKarwaiMWIxabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase II studies [abstract]Cancer Res200969Suppl394S
   Google Scholar
• RugoHSRochéHThomasEIxabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies [abstract]Cancer Res200969Suppl225S
   Google Scholar
• SmithJWVukeljaSJRabeACPreliminary toxicity results of a phase II randomized trial of weekly or every-3-week ixabepilone in metastatic breast cancer (MBC) [abstract]Presented at the 32nd Annual San Antonio Breast Cancer Symposium2009 Dec 10–13San Antonio, TX, USA
   Google Scholar
• Ixempra [package insert]Princeton, NJBristol-Myers Squibb2009
   Google Scholar
• LeeJJSwainSMPeripheral neuropathy induced by microtubule-stabilizing agentsJ Clin Oncol2006241633164216575015
   PubMed Web of Science ®Google Scholar
• SwainSMArezzoJCNeuropathy associated with microtubule inhibitors: diagnosis, incidence, and managementClin Adv Hematol Oncol2008645546718567992
   PubMedGoogle Scholar
• LeeJJLowJACroarkinEChanges in neurologic function tests may predict neurotoxicity caused by ixabepiloneJ Clin Oncol2006242084209116648510
   PubMed Web of Science ®Google Scholar
• OrsiniLSMukhopadhyayPPeckRCorey-LislePQuality adjusted time without symptoms or toxicities (Q-TWiST) of ixabepilone plus capecitabine versus capecitabine for metastatic breast cancer (MBC) [abstract]Presented at the 2009 ASCO Breast Cancer Symposium2009 Oct 8–10San Francisco, CA, USA
   Google Scholar